• Introduction:

    Dr. Pankit Vachhani is an Assistant Professor of Medicine at the University of Alabama at Birmingham and Associate Scientist of Experimental Therapeutics. He graduated from Weill Cornell Medical College in Qatar in 2012 and on to complete his internal medicine residency at Virginia Commonwealth University, followed by a fellowship in hematology/oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY.

    Clinical Interests & Research:

    At UAB, he is involved in multiple clinical trials as a principal investigator. He leads the Leukemia/BMT working group. His primary research interest is in hematological malignancies, particularly myeloproliferative neoplasms and AML, where he focuses on experimental therapeutics. He also serves as a panelist helping create the AML and MPN Treatment Guidelines for the National Comprehensive Cancer Network.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia.Blood2022
    2022 Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During PregnancyJournal of Adolescent and Young Adult Oncology.  11:617-620. 2022
    2022 Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US 2022
    2022 Myeloproliferative Neoplasms, Version 3.2022Journal of the National Comprehensive Cancer Network : JNCCN.  20:1033-1062. 2022
    2022 Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemiaBritish Journal of Haematology.  198:e35-e37. 2022
    2022 Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AMLBlood.  139:3546-3557. 2022
    2022 Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemiaLeukemia Research.  117. 2022
    2022 Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients with Myelofibrosis with Progression or Suboptimal Response: Phase II Safety and EfficacyJournal of Clinical Oncology.  40:1671-1680. 2022
    2022 How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient OutcomesCurrent Treatment Options in Oncology.  23:688-702. 2022
    2022 Disease Modification in Myelofibrosis: An Elusive Goal?Journal of Clinical Oncology.  40:1147-1154. 2022
    2022 Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents 2022
    2022 IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemiaCancer Treatment and Research Communications.  31. 2022
    2022 North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needBlood2022
    2022 Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approvalLeukemia Research.  112. 2022
    2021 Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaBlood.  138:387-400. 2021
    2021 Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.Blood.  138:387-400. 2021
    2021 A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemiaLeukemia Research.  107. 2021
    2021 Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditisJournal for ImmunoTherapy of Cancer.  9. 2021
    2021 Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN GuidelinesJournal of the National Comprehensive Cancer Network : JNCCN.  19:16-27. 2021
    2021 Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia 2021
    2020 Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, version 3.2021Journal of the National Comprehensive Cancer Network : JNCCN.  18:1248-1269. 2020
    2020 Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case SeriesHematology/Oncology and Stem Cell Therapy.  13:143-146. 2020
    2020 Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors 2020
    2020 Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyJournal for ImmunoTherapy of Cancer.  8. 2020
    2020 Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow ResultsClinical Lymphoma, Myeloma and Leukemia.  20:31-38. 2020
    2019 Acute promyelocytic leukemia during pregnancy: A case report and 10-year institutional review of hematologic malignancies during pregnancy 2019
    2019 Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionBlood.  134:48. 2019
    2019 Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphomaBritish Journal of Haematology.  184:674-676. 2019
    2019 Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureCase Reports in Oncology.  12:260-276. 2019
    2018 Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experienceLeukemia Research.  75:29-35. 2018
    2018 All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisisLeukemia Research Reports.  10:16-19. 2018
    2017 Treatment of Relapsed/Refractory Acute Myeloid LeukemiaCurrent Treatment Options in Oncology.  18. 2017
    2017 Dexrazoxane for cardioprotection in older adults with acute myeloid leukemiaLeukemia Research Reports.  7:36-39. 2017
    2017 Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Case Reports in Hematology.  2017:9681832. 2017
    2016 VEGF inhibitors in renal cell carcinomaClinical advances in hematology & oncology : H&O.  14:1016-1028. 2016
    2016 Spotlight on pembrolizumab in non-small cell lung cancer: The evidence to dateOncoTargets and Therapy.  9:5855-5866. 2016
    2016 Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.Case Reports in Hematology.  2016:1259759. 2016
    2014 Remission of rheumatoid arthritis on brentuximab vedotinRheumatology.  53:2314-2315. 2014
    2014 Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AMLPhysiological Genomics.  46:448-456. 2014
    2014 Isolated gastric myeloid sarcoma: a case report and review of the literature.Case Reports in Hematology.  2014:541807. 2014
    2013 Maternal complications and neonatal outcome in Arab women of a fast developing countryJournal of Family and Community Medicine.  20:27-34. 2013
    2011 Obesity and low vision as a result of excessive Internet use and television viewingInternational Journal of Food Sciences and Nutrition.  62:60-62. 2011
    2010 Do excessive internet use, television viewing and poor lifestyle habits affect low vision in school children?Journal of Child Health Care.  14:375-385. 2010


    Year Title Altmetric
    2014 Can we cure CML without transplantation?.  279-326. 2014

    Research Overview

  • Dr Vachhani’s primary interest is in hematological malignancies, particularly acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). His specific research interests include developmental therapeutics and clinical trials for high-risk, elderly and relapsed AML.
  • Education And Training

  • Doctor of Medicine, 2012
  • Full Name

  • Pankit Vachhani